ES2211899T3 - Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos. - Google Patents

Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos.

Info

Publication number
ES2211899T3
ES2211899T3 ES95909730T ES95909730T ES2211899T3 ES 2211899 T3 ES2211899 T3 ES 2211899T3 ES 95909730 T ES95909730 T ES 95909730T ES 95909730 T ES95909730 T ES 95909730T ES 2211899 T3 ES2211899 T3 ES 2211899T3
Authority
ES
Spain
Prior art keywords
apo
compound
domain
extracellular
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909730T
Other languages
English (en)
Spanish (es)
Inventor
Peter Krammer
Michael Westendorp
Klaus Schulze-Osthoff
Klaus-Michael Debatin
Rainer Frank
Jens Dhein
Henning Walczak
Eckart Knipping
Kirstin Stricker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944412177 external-priority patent/DE4412177C1/de
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2211899T3 publication Critical patent/ES2211899T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES95909730T 1994-04-08 1995-02-16 Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos. Expired - Lifetime ES2211899T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4412177 1994-04-08
DE19944412177 DE4412177C1 (de) 1994-04-08 1994-04-08 Hemmer von Apoptose

Publications (1)

Publication Number Publication Date
ES2211899T3 true ES2211899T3 (es) 2004-07-16

Family

ID=6514949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909730T Expired - Lifetime ES2211899T3 (es) 1994-04-08 1995-02-16 Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos.

Country Status (8)

Country Link
US (1) US20070207160A1 (https=)
EP (1) EP0705278B1 (https=)
JP (2) JP3778453B2 (https=)
AT (1) ATE255129T1 (https=)
DE (1) DE4447484C2 (https=)
DK (1) DK0705278T3 (https=)
ES (1) ES2211899T3 (https=)
WO (1) WO1995027735A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2215905A1 (en) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. Monoclonal antibody reacting specifically with fas ligand and process for producing the same
WO1996040041A2 (en) * 1995-06-07 1996-12-19 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
DE19544333C2 (de) * 1995-11-28 1998-12-10 Deutsches Krebsforsch Verfahren zur Beurteilung der Aktivität von Arzneistoffen
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
GB9703276D0 (en) * 1997-02-17 1997-04-09 Screaton Gavin R Materials and methods relating to the protection of useful immune cells
CA2308017A1 (en) * 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
PT1606318E (pt) 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
CN102497886B (zh) * 2009-07-21 2016-01-20 玛丽皇后与斯特菲尔德学院 用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
CN104640568B (zh) 2012-07-18 2016-10-19 阿珀吉尼科斯股份公司 用于治疗mds的cd95信号传导途径的抑制剂
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
KR20200003913A (ko) 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
PT90657B (pt) * 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
AU7677891A (en) * 1990-03-30 1991-10-30 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
WO1995010540A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
JPH08511692A (ja) 1996-12-10
JP3778453B2 (ja) 2006-05-24
DE4447484C2 (de) 1997-07-17
DK0705278T3 (da) 2004-03-22
EP0705278A1 (de) 1996-04-10
EP0705278B1 (de) 2003-11-26
WO1995027735A1 (de) 1995-10-19
JP2004215669A (ja) 2004-08-05
JP3811745B2 (ja) 2006-08-23
ATE255129T1 (de) 2003-12-15
DE4447484A1 (de) 1995-10-26
US20070207160A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
ES2211899T3 (es) Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos.
DK174927B1 (da) DNA, der koder for human faktor VIII:C, vektor omfattende denne DNA, transformeret vært omfattende denne DNA, og fremgangsmåde til fremstilling af human faktor VIII:C
ES2287950T3 (es) Proteina receptora designada 2f1.
JPH07501698A (ja) 二価特異性ヘテロ二量体
US7825085B2 (en) Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
WO1998055620A1 (en) Ntn-2 member of tnf ligand family
JPH07508639A (ja) 腫瘍壊死因子受容体を含む融合蛋白質
WO1998055621A1 (en) Ntn-2 member of tnf ligand family
CA2000821A1 (en) Inhibitors of platelet binding
RU98112759A (ru) Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах
JP3784078B2 (ja) 可溶性ｌｄｌリセプター
US11865181B2 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
JPS61108397A (ja) インタ−フエロン−γ蛋白質の製造法
US20070015258A1 (en) Alpha-beta C4BP -type recombinant heteromultimeric proteins
US20110098226A1 (en) Small molecular weight TNF receptor multimeric molecule
US6369198B1 (en) Allelic variant of human STAT3
US20230203204A1 (en) Fusion protein, preparation method therefor and use thereof
WO1999021997A1 (en) Viral encoded semaphorin protein receptor dna and polypeptides
US20070110742A1 (en) Recombinant peptide vector comprising the gene for treatment for autoimmune diseases
US6562797B1 (en) Methods and compositions for regulating FAS-associated apoptosis
KR100418329B1 (ko) 직렬 연쇄체를 갖는 면역접합체
US6174689B1 (en) Viral encoded semaphorin protein receptor DNA and polypeptides
US7214497B2 (en) Viral encoded semaphorin protein receptor DNA and polypeptides
WO1995004756A1 (en) Complement inhibitor proteins of non-human primates
US6562949B1 (en) Antibodies to viral encoded semaphorin protein receptor polypeptides